Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model

Neoplasia

Volumn 11, Issue 9, 2009, Pages 934-944

  Benten, Daniel ^a   Keller, Gunhild ^a   Quaas, Alexander ^a   Schrader, Jorg ^a   Gontarewicz, Artur ^a   Balabanov, Stefan ^a   Braig, Melanie ^a   Wege, Henning ^a   Moll, Jurgen ^b   Lohse, Ansgar W ^a   Brummendorf, Tim H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; HISTONE H3; PHA 739358; SERINE; SORAFENIB; STATHMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; ENDOREDUPLICATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IC 50; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE MICROARRAY; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 69249147760     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09664     Document Type: Article

References (48)

1. El-Serag HB and Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576.
2. Leong TY and Leong AS (2005). Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 7, 5-15.
3. Llovet JM and Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378-390.
5. Zhu AX (2008). Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112, 250-259.
6. Keen N and Taylor S (2004). Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4, 927-936.
7. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, and Gandara DR (2008). Aurora kinases as anticancer drug targets. Clin Cancer Res 14, 1639-1648.
8. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, et al. (2007). PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 6, 3158-3168.
9. Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, et al. (2008). Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111, 4355-4364.
10. Jeng YM, Peng SY, Lin CY, and Hsu HC (2004). Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 10, 2065-2071.
11. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, et al. (2008). Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95, 611-619.
12. Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, Chen TJ, Kuo SH, Hsu C, Hu FC, et al. (2009). The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 50, 518-527.
13. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, and Santoro M (2006). BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98, 326-334.
14. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M, Lebeau A, Terracciano L, Al-Kuraya K, Janicke F, et al. (2007). Estrogen receptor α (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39, 655-660.
15. - T cells into iTreg. PLoS ONE 3, e3302.
16. Hirota T, Lipp JJ, Toh BH, and Peters JM (2005). Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature 438, 1176-1180.
17. Redeker V, Lachkar S, Siavoshian S, Charbaut E, Rossier J, Sobel A, and Curmi PA (2000). Probing the native structure of stathmin and its interaction domains with tubulin. Combined use of limited proteolysis, size exclusion chromatography, and mass spectrometry. J Biol Chem 275, 6841-6849.
18. Gadea BB and Ruderman JV (2006). Aurora B is required for mitotic chromatininduced phosphorylation of Op18/Stathmin. Proc Natl Acad Sci USA 103, 4493-4498.
19. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, and Breuhahn K (2007). Protumorigenic overexpression of stathmin/Op18 by gainof-function mutation in p53 in human hepatocarcinogenesis. Hepatology 46, 759-768.
20. Rubin CI and Atweh GF (2004). The role of stathmin in the regulation of the cell cycle. J Cell Biochem 93, 242-250.
21. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, and Carter C (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851-11858.
22. Girdler F, Gascoigne KE, Eyers PA, Hartmuth S, Crafter C, Foote KM, Keen NJ, and Taylor SS (2006). Validating Aurora B as an anti-cancer drug target. J Cell Sci 119, 3664-3675.
23. Yang H, Burke T, Dempsey J, Diaz B, Collins E, Toth J, Beckmann R, and Ye X (2005). Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase. FEBS Lett 579, 3385-3391.
24. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, and Cotler SJ (2005). p53, Ki-67, and serum α feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 18, 1498-1503.
25. Schmitt-Graff A, Ertelt V, Allgaier HP, Koelble K, Olschewski M, Nitschke R, Bochaton-Piallat ML, Gabbiani G, and Blum HE (2003). Cellular retinol-binding protein-1 in hepatocellular carcinoma correlates with β-catenin, Ki-67 index, and patient survival. Hepatology 38, 470-480.
26. Chieffi P, Cozzolino L, Kisslinger A, Libertini S, Staibano S,Mansueto G, De Rosa G, Villacci A, Vitale M, Linardopoulos S, et al. (2006). Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 66, 326-333.
27. Kurai M, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Kashima H, Suzuki A, and Konishi I (2005). Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36, 1281-1288.
28. Midorikawa Y, Tsutsumi S, Nishimura K, Kamimura N, Kano M, Sakamoto H, Makuuchi M, and Aburatani H (2004). Distinct chromosomal bias of gene expression signatures in the progression of hepatocellular carcinoma. Cancer Res 64, 7263-7270.
29. Baudis M (2007). Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 7, 226.
30. PHA-739358 for treatment of hormone refractory prostate cancer. ClinicalTrials. gov Identifier: NCT00766324. 2007.
31. PHA-739358 in treating patients with chronic myelogenous leukemia that relapsed after imatinib mesylate or c-ABL therapy. ClinicalTrials.gov Identifier: NCT00335868. 2007.
32. Jackson PE, Qian GS, Friesen MD, Zhu YR, Lu P, Wang JB, Wu Y, Kensler TW, Vogelstein B, and Groopman JD (2001). Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 61, 33-35.
33. Tannapfel A, Busse C, Weinans L, Benicke M, Katalinic A, Geissler F, Hauss J, and Wittekind C (2001). INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 20, 7104-7109.
34. Vogel C, Hager C, and Bastians H (2007). Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res 67, 339-345.
35. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, and Cheng JQ (2004). Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 279, 52175-52182.
36. Mao JH, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW, and Balmain A (2007). Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell 11, 161-173.
37. Paquette R, Shah N, Sawyers CL, Martinelli G, John N, Chalukya M, Rocchetti M, Fiocchi C, Comis S, Capolongo L, et al. (2007). PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL. Blood 110 (11, Pt 1); Abstract no. 1030.
38. Koike K, Takaki A, Tatsukawa M, Suzuki M, Shiraha H, Iwasaki Y, Sakaguchi K, and Shiratori Y (2006). Combination of 5-FU and IFNá enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. Int J Oncol 29, 1253-1261.
39. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, and Anania FA (2007). Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67, 2497-2507.
40. Yang H, He L, Kruk P, Nicosia SV, and Cheng JQ (2006). Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119, 2304-2312.
41. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, and Harris CC (1993). p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 14, 987-992.
42. Puisieux A, Galvin K, Troalen F, Bressac B, Marcais C, Galun E, Ponchel F, Yakicier C, Ji J, and OzturkM (1993). Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J 7, 1407-1413.
43. Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, Wilkens L, Destro A, Fiamengo B, Manns MP, et al. (2007). Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology 45, 968-976.
44. Willenbring H, Sharma AD,Vogel A, LeeAY, Rothfuss A,Wang Z, Finegold M, and Grompe M (2008). Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 14, 59-67.
45. Dar AA, Belkhiri A, Ecsedy J, Zaika A, and El-Rifai W (2008). Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68, 8998-9004.
46. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, and Shapiro GI (2006). The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66, 7668-7677.
47. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, Lin CY, Lee PH, and Hsu HC (2006). Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 209, 549-558.
48. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, et al. (2008). Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (6), 1972-1983; 1983.e1-e11.